Department of Nephrology, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, China.
Nephropathy Clinical Medical Research Center of Sichuan Province, Luzhou 646000, China.
J Tradit Chin Med. 2022 Feb;42(1):39-48. doi: 10.19852/j.cnki.jtcm.2022.01.004.
To investigate the efficacy of Shenweifang (SWF)-containing serum on transforming growth factor (TGF)-β1-induced fibroblast-myofibroblast transition in normal rat kidney interstitial fibroblast cells (NRK-49F).
Sprague-Dawley rats were gavaged with one of five solutions: (a) saline; (b) saline plus low-dose SWF; (c) saline plus medium-dose SWF; (d) saline plus highdose SWF; and (e) saline plus valsartan. NRK-49F cells were treated with TGF-β1 and cultured using serum from the gavaged rats.
TGF-β1 treatment increased the expression of α-smooth muscle actin, proliferating cell nuclear antigen, collagen I, Smad3, mitogen-activated protein kinase (MAPK) 10, and c-Jun N-terminal kinase (JNK) 3 and induced abnormalities in cell morphology, cell cycle progression, and cell proliferation.
SWF- or valsartan-containing serum corrected (or partially corrected) TGF-β1-induced abnormal changes in this in vitro system. SWF-containing serum reversed abnormalities in morphology, cell cycle progression, and proliferation in TGF-β1-treated NRK49F cells, probably by blocking the TGF-β1/Smads and TGF-β1/MAPK/JNK pathways.
观察参味方含药血清对转化生长因子-β1（TGF-β1）诱导的正常大鼠肾间质成纤维细胞（NRK-49F）转分化为肌成纤维细胞的影响。
SD 大鼠灌胃给予生理盐水和不同剂量参味方（低、中、高剂量）及缬沙坦，制备含药血清。体外培养 NRK-49F 细胞，分为正常对照组、TGF-β1 模型组、TGF-β1+参味方低、中、高剂量组、TGF-β1+缬沙坦组，采用 Western blot 法检测细胞中α-平滑肌肌动蛋白（α-SMA）、增殖细胞核抗原（PCNA）、Ⅰ型胶原（ColⅠ）、Smad3、丝裂原活化蛋白激酶 10（MAPK10）和 c-Jun N-末端激酶（JNK）3 的表达，观察细胞形态学变化，流式细胞术检测细胞周期，四甲基偶氮唑盐比色法（MTT）检测细胞增殖。
TGF-β1 可增加α-SMA、PCNA、ColⅠ、Smad3、MAPK10 和 JNK3 的表达，引起细胞形态改变、细胞周期异常和增殖增加；参味方或缬沙坦含药血清可部分纠正 TGF-β1 诱导的上述改变。
参味方含药血清可能通过抑制 TGF-β1/Smads 和 TGF-β1/MAPK/JNK 信号通路，部分纠正 TGF-β1 诱导的 NRK-49F 细胞形态、细胞周期和增殖异常。
